Antitrust

Chairman Nadler Statement for the Markup of H.R. 2374, the Stop STALLING Act

| Posted in Press Releases
Tags: Antitrust

Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 2374, the Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (Stop STALLING Act): “H.R. 2374, the ‘Stop STALLING Act,’ takes an important step toward lowering drug prices and increasing competition in health care markets. It does t... Read more »

Chairman Nadler Statement for the Markup of H.R. 2376, the Prescription Pricing for the People Act of 2019

| Posted in Press Releases
Tags: Antitrust

Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 2376, the Prescription Pricing for the People Act of 2019: “H.R. 2376, the ‘Prescription Pricing for the People Act of 2019,’ would require the Federal Trade Commission to conduct a comprehensive report on the state of competition in the drug supply chain. “In particular... Read more »

Chairman Nadler Statement for the Markup of H.R. 965, the CREATES Act

| Posted in Press Releases
Tags: Antitrust

Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 (CREATES Act): “H.R. 965, the ‘Creating and Restoring Equal Access to Equivalent Samples Act of 2019,’ or the ‘CREATES Act,’ is bipartisan legislation that would substantially lower drug price... Read more »

Chairman Nadler Statement for the Markup of H.R. 2375, the Preserve Access to Affordable Generics and Biosimilars Act

| Posted in Press Releases
Tags: Antitrust

Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 2375, the Preserve Access to Affordable Generics and Biosimilars Act: “H.R. 2375, the ‘Preserve Access to Affordable Generics and Biosimilars Act’ is one of a series of bipartisan measures that we are considering today to address the critical need to lower the soaring co... Read more »

Tomorrow: House Judiciary to Markup Bipartisan Bills to Lower Prescription Drug Prices

| Posted in Press Releases
Tags: Antitrust

On April 30, 2019 at 2pm, the House Judiciary Committee will consider four bills to address prescription drug pricing, including H.R. 965, the CREATES Act; H.R. 2375, the Preserve Access to Affordable Generics and Biosimilars Act; H.R. 2374, the Stop STALLING Act; and H.R. 2376, the Prescription Pricing for the People Act of 2019. Date: April 30, 2019 Time: 2:00 p.m. Location: 2141 Rayburn House O... Read more »

Nadler & Collins Introduce Preserve Access to Affordable Generics and Biosimilars Act, Legislation to Lower Prescription Drug Prices

| Posted in Press Releases
Tags: Antitrust

Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) and Ranking Member Doug Collins (R-GA) introduced H.R. 2375, the bipartisan Preserve Access to Affordable Generics and Biosimilars Act. This legislation strengthens the Federal Trade Commission’s (FTC) ability to challenge settlement agreements between large brand drug companies and generic drug companies in court, which will help low... Read more »

Nadler & Collins Introduce Prescription Pricing for the People Act of 2019

| Posted in Press Releases
Tags: Antitrust

Washington, D.C. — Reps. Jerrold Nadler (D-N.Y.), Chairman of the House Judiciary Committee and Doug Collins (R-Ga.), Ranking Member of the House Judiciary Committee, today introduced the Prescription Pricing for the People Act of 2019. The legislation requires the Federal Trade Commission (FTC) to study pharmacy benefits managers (PBMs) and how their actions are affecting patients and local pharm... Read more »

Nadler & Cicilline Statement on White House Refusal to Provide Answers on Interference with AT&T-Time Warner Merger

| Posted in Press Releases

Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) and Antitrust Subcommittee Chairman David N. Cicilline (D-RI) released a joint statement in response to the White House’s refusal to provide answers related to their potential interference with the merger of AT&T and Time Warner: “Antitrust enforcement is law enforcement. It must be guided by the rule of law, not used as a political c... Read more »

Chairman Nadler Opening Statement for the Subcommittee Hearing on “The State of Competition in the Wireless Market: Examining the Impact of the Proposed Merger of T-Mobile and Sprint on Consumers, Workers, and the Internet” 

| Posted in Press Releases
Tags: Antitrust

Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening remarks during a Subcommittee on Antitrust, Commercial, and Administrative Law hearing on the impact of the proposed merger of T-Mobile and Sprint on consumers, workers, and the Internet: “Thank you, Mr. Chairman. I appreciate this opportunity to consider carefully the impact of the proposed merger of S... Read more »

Nadler, Cicilline Press for Answers on Whether White House Interfered with AT&T-Time Warner Merger

| Posted in Press Releases

Following reports that President Donald Trump directed then-National Economic Council Director Gary Cohn to use the Justice Department to block AT&T’s proposed acquisition of Time Warner, a move that could benefit Fox News and hurt CNN, House Judiciary Committee Chairman Jerrold Nadler (D-NY) and Antitrust Subcommittee Chairman David N. Cicilline (D-RI) are requesting the White House and Departmen... Read more »